const interactionStatements = [
    { code: 1, statement: "#Drug1 may increase the photosensitizing activities of #Drug2." },
    { code: 2, statement: "#Drug1 may increase the anticholinergic activities of #Drug2." },
    { code: 3, statement: "The bioavailability of #Drug2 can be decreased when combined with #Drug1." },
    { code: 4, statement: "The metabolism of #Drug2 can be increased when combined with #Drug1." },
    { code: 5, statement: "#Drug1 may decrease the vasoconstricting activities of #Drug2." },
    { code: 6, statement: "#Drug1 may increase the anticoagulant activities of #Drug2." },
    { code: 7, statement: "#Drug1 may increase the ototoxic activities of #Drug2." },
    { code: 8, statement: "The therapeutic efficacy of #Drug2 can be increased when used in combination with #Drug1." },
    { code: 9, statement: "#Drug1 may increase the hypoglycemic activities of #Drug2." },
    { code: 10, statement: "#Drug1 may increase the antihypertensive activities of #Drug2." },
    { code: 11, statement: "The serum concentration of the active metabolites of #Drug2 can be reduced when #Drug2 is used in combination with #Drug1 resulting in a loss in efficacy." },
    { code: 12, statement: "#Drug1 may decrease the anticoagulant activities of #Drug2." },
    { code: 13, statement: "The absorption of #Drug2 can be decreased when combined with #Drug1." },
    { code: 14, statement: "#Drug1 may decrease the bronchodilatory activities of #Drug2." },
    { code: 15, statement: "#Drug1 may increase the cardiotoxic activities of #Drug2." },
    { code: 16, statement: "#Drug1 may increase the central nervous system depressant (CNS depressant) activities of #Drug2." },
    { code: 17, statement: "#Drug1 may decrease the neuromuscular blocking activities of #Drug2." },
    { code: 18, statement: "#Drug1 can cause an increase in the absorption of #Drug2 resulting in an increased serum concentration and potentially a worsening of adverse effects." },
    { code: 19, statement: "#Drug1 may increase the vasoconstricting activities of #Drug2." },
    { code: 20, statement: "#Drug1 may increase the QTc-prolonging activities of #Drug2." },
    { code: 21, statement: "#Drug1 may increase the neuromuscular blocking activities of #Drug2." },
    { code: 22, statement: "#Drug1 may increase the adverse neuromuscular activities of #Drug2." },
    { code: 23, statement: "#Drug1 may increase the stimulatory activities of #Drug2." },
    { code: 24, statement: "#Drug1 may increase the hypocalcemic activities of #Drug2." },
    { code: 25, statement: "#Drug1 may increase the atrioventricular blocking (AV block) activities of #Drug2." },
    { code: 26, statement: "#Drug1 may decrease the antiplatelet activities of #Drug2." },
    { code: 27, statement: "#Drug1 may increase the neuroexcitatory activities of #Drug2." },
    { code: 28, statement: "#Drug1 may increase the dermatologic adverse activities of #Drug2." },
    { code: 29, statement: "#Drug1 may decrease the diuretic activities of #Drug2." },
    { code: 30, statement: "#Drug1 may increase the orthostatic hypotensive activities of #Drug2." },
    { code: 31, statement: "The risk or severity of hypertension can be increased when #Drug2 is combined with #Drug1." },
    { code: 32, statement: "#Drug1 may increase the sedative activities of #Drug2." },
    { code: 33, statement: "The risk or severity of QTc prolongation can be increased when #Drug1 is combined with #Drug2." },
    { code: 34, statement: "#Drug1 may increase the immunosuppressive activities of #Drug2." },
    { code: 35, statement: "#Drug1 may increase the neurotoxic activities of #Drug2." },
    { code: 36, statement: "#Drug1 may increase the antipsychotic activities of #Drug2." },
    { code: 37, statement: "#Drug1 may decrease the antihypertensive activities of #Drug2." },
    { code: 38, statement: "#Drug1 may increase the vasodilatory activities of #Drug2." },
    { code: 39, statement: "#Drug1 may increase the constipating activities of #Drug2." },
    { code: 40, statement: "#Drug1 may increase the respiratory depressant activities of #Drug2." },
    { code: 41, statement: "#Drug1 may increase the hypotensive and central nervous system depressant (CNS depressant) activities of #Drug2." },
    { code: 42, statement: "The risk or severity of hyperkalemia can be increased when #Drug1 is combined with #Drug2." },
    { code: 43, statement: "The protein binding of #Drug2 can be decreased when combined with #Drug1." },
    { code: 44, statement: "#Drug1 may increase the central neurotoxic activities of #Drug2." },
    { code: 45, statement: "#Drug1 may decrease effectiveness of #Drug2 as a diagnostic agent." },
    { code: 46, statement: "#Drug1 may increase the bronchoconstrictory activities of #Drug2." },
    { code: 47, statement: "The metabolism of #Drug2 can be decreased when combined with #Drug1." },
    { code: 48, statement: "#Drug1 may increase the myopathic rhabdomyolysis activities of #Drug2." },
    { code: 49, statement: "The risk or severity of adverse effects can be increased when #Drug1 is combined with #Drug2." },
    { code: 50, statement: "The risk or severity of heart failure can be increased when #Drug2 is combined with #Drug1." },
    { code: 51, statement: "#Drug1 may increase the hypercalcemic activities of #Drug2." },
    { code: 52, statement: "#Drug1 may decrease the analgesic activities of #Drug2." },
    { code: 53, statement: "#Drug1 may increase the antiplatelet activities of #Drug2." },
    { code: 54, statement: "#Drug1 may increase the bradycardic activities of #Drug2." },
    { code: 55, statement: "#Drug1 may increase the hyponatremic activities of #Drug2." },
    { code: 56, statement: "The risk or severity of hypotension can be increased when #Drug1 is combined with #Drug2." },
    { code: 57, statement: "#Drug1 may increase the nephrotoxic activities of #Drug2." },
    { code: 58, statement: "#Drug1 may decrease the cardiotoxic activities of #Drug2." },
    { code: 59, statement: "#Drug1 may increase the ulcerogenic activities of #Drug2." },
    { code: 60, statement: "#Drug1 may increase the hypotensive activities of #Drug2." },
    { code: 61, statement: "#Drug1 may decrease the stimulatory activities of #Drug2." },
    { code: 62, statement: "The bioavailability of #Drug2 can be increased when combined with #Drug1." },
    { code: 63, statement: "#Drug1 may increase the myelosuppressive activities of #Drug2." },
    { code: 64, statement: "#Drug1 may increase the serotonergic activities of #Drug2." },
    { code: 65, statement: "#Drug1 may increase the excretion rate of #Drug2 which could result in a lower serum level and potentially a reduction in efficacy." },
    { code: 66, statement: "The risk or severity of bleeding can be increased when #Drug1 is combined with #Drug2." },
    { code: 67, statement: "#Drug1 can cause a decrease in the absorption of #Drug2 resulting in a reduced serum concentration and potentially a decrease in efficacy." },
    { code: 68, statement: "#Drug1 may increase the hyperkalemic activities of #Drug2." },
    { code: 69, statement: "#Drug1 may increase the analgesic activities of #Drug2." },
    { code: 70, statement: "The therapeutic efficacy of #Drug2 can be decreased when used in combination with #Drug1." },
    { code: 71, statement: "#Drug1 may increase the hypertensive activities of #Drug2." },
    { code: 72, statement: "#Drug1 may decrease the excretion rate of #Drug2 which could result in a higher serum level." },
    { code: 73, statement: "The serum concentration of #Drug2 can be increased when it is combined with #Drug1." },
    { code: 74, statement: "#Drug1 may increase the fluid retaining activities of #Drug2." },
    { code: 75, statement: "The serum concentration of #Drug2 can be decreased when it is combined with #Drug1." },
    { code: 76, statement: "#Drug1 may decrease the sedative activities of #Drug2." },
    { code: 77, statement: "The serum concentration of the active metabolites of #Drug2 can be increased when #Drug2 is used in combination with #Drug1." },
    { code: 78, statement: "#Drug1 may increase the hyperglycemic activities of #Drug2." },
    { code: 79, statement: "#Drug1 may increase the central nervous system depressant (CNS depressant) and hypertensive activities of #Drug2." },
    { code: 80, statement: "#Drug1 may increase the hepatotoxic activities of #Drug2." },
    { code: 81, statement: "#Drug1 may increase the thrombogenic activities of #Drug2." },
    { code: 82, statement: "#Drug1 may increase the arrhythmogenic activities of #Drug2." },
    { code: 83, statement: "#Drug1 may increase the hypokalemic activities of #Drug2." },
    { code: 84, statement: "#Drug1 may increase the vasopressor activities of #Drug2." },
    { code: 85, statement: "#Drug1 may increase the tachycardic activities of #Drug2." },
    { code: 86, statement: "The risk of a hypersensitivity reaction to #Drug2 is increased when it is combined with #Drug1." }
  ];
  
  export default interactionStatements